The Companion Diagnostic Market is projected to grow at ~13% by 2027, fueled by personalized medicine, medical tech advancements, affordable genetic tests, increasing adverse drug reactions, and demand for next-gen sequencing.
Demand for personalized medicine, reduced costs of genetic-based CDx tests, growing cases of drug reactions & its side effects and an increasing demand for next-generation sequencing are the key factors driving the companion diagnostics market.
